The effects of bufadienolides on HER2 overexpressing breast cancer cells

被引：10
|
作者：
Wang, Tianjiao [1 ]
Mu, Lin [2 ]
Jin, Haifeng [1 ]
Zhang, Peng [1 ]
Wang, Yueyue [1 ]
Ma, Xiaochi [2 ]
Pan, Jinjin [1 ]
Miao, Jian [3 ]
Yuan, Yuhui [1 ]
机构：
[1] Dalian Med Univ, Ctr Canc, Inst Canc Stem Cell, Dalian, Peoples R China
[2] Dalian Med Univ, Coll Pharm, Dalian, Peoples R China
[3] Dalian Med Univ, Affiliated Hosp 2, Dept Gen Surg, Dalian, Peoples R China
来源：
TUMOR BIOLOGY | 2016年 / 37卷 / 06期
基金：
中国国家自然科学基金;
关键词：
Breast cancer; HER2; SRC-1; SRC-3; GROWTH-FACTOR-RECEPTOR; TAMOXIFEN RESISTANCE; TOAD VENOM; COACTIVATOR AIB1; ESTROGEN; ARENOBUFAGIN; SRC-3; PROLIFERATION; TRANSCRIPTION; MECHANISMS;
D O I：
10.1007/s13277-015-4381-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
HER2 is a proto-oncogene frequently amplified in human breast cancer, its overexpression is correlated with tamoxifen resistance and decreased recurrence-free survival. Arenobufagin and bufalin are homogeneous bufadienolides of cardiac glycosides agents. In this research, we studied the effects of arenobufagin and bufalin on cellular survival and proliferation of HER2 overexpressing breast cancer cells and the mechanism under the results including the direct effect on HER2 downstream pathways. Our results showed that arenobufagin and bufalin could significantly inhibit the proliferation and survival of HER2 overexpressing breast cancer cells, along with the declination of SRC-1, SRC-3, nuclear transcription factor E2F1, phosphorylated AKT, and ERK. And the combination of each bufadienolide in low dose with tamoxifen could significantly enhance the inhibitory effect of tamoxifen on HER2 overexpressing breast cancer cells. All above suggest that arenobufagin and bufalin may be potential therapy adjuvants for HER2 overexpressing breast cancer therapy.
引用
收藏
页码：7155 / 7163
页数：9
相关论文
共 50 条
  • [41] Effects of trastuzumab and paclitaxel in HER2-overexpressing breast cancer
    Li, Songhua
    Higuchi, Hideo
    Ohuchi, Noriaki
    FUTURE MEDICAL ENGINEERING BASED ON BIONANOTECHNOLOGY, PROCEEDINGS, 2006, : 395 - +
  • [42] Quantitative proteomic analysis of HER2 normal and overexpressing MCF-7 breast cancer cells revealed proteomic changes accompanied with HER2 gene amplification
    Tang, Yanan
    Mackey, John
    Lai, Raymond
    Ghosh, Sunita
    Santos, Cheryl
    Graham, Kathryn
    Damaraju, Sambasivarao
    Pasdar, Manijeh
    Li, Liang
    JOURNAL OF PROTEOMICS, 2013, 91 : 200 - 209
  • [43] Immune microenvironment dynamics of HER2 overexpressing breast cancer under dual anti-HER2 blockade
    Batalha, Sofia
    Gomes, Catarina Monteiro
    Brito, Catarina
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [44] Safety and effectiveness of anti-HER2 therapy in patients with advanced metastatic tissue HER2-negative breast cancer with elevated serum HER2 and/or HER2 overexpressing circulating tumor cells
    Kurbacher, C. M.
    Eichler, C.
    Quade, A. B.
    Kunstmann, G.
    Herz, S.
    Kurbacher, J. A.
    Warm, M. R.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S40 - S40
  • [45] Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells
    Fischgraebe, Jeanett
    Goette, Martin
    Michels, Katharina
    Kiesel, Ludwig
    Wuelfing, Pia
    INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (03) : 696 - 706
  • [46] Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 Abundance
    Emde, Anna
    Mahlknecht, Georg
    Maslak, Kerstin
    Ribba, Benjamin
    Sela, Michael
    Possinger, Kurt
    Yarden, Yosef
    TRANSLATIONAL ONCOLOGY, 2011, 4 (05): : 293 - 300
  • [47] Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer
    Zhang, J. -L.
    Yao, Q.
    Chen, J. -H.
    Wang, Y.
    Wang, H.
    Fan, Q.
    Ling, R.
    Yi, J.
    Wang, L.
    GENETICS AND MOLECULAR RESEARCH, 2015, 14 (01) : 2099 - 2103
  • [48] Characterization of the HER2 status on circulating breast cancer cells
    Alix-Panabieres, C.
    Riethdorf, S.
    Fehm, T.
    Vendrell, J-P
    Pantel, K.
    CANCER RESEARCH, 2009, 69 (02) : 306S - 306S
  • [49] Development and effects of immunoliposomes carrying an antisense oligonucleotide against DHFR RNA and directed toward human breast cancer cells overexpressing HER2
    Rodríguez, M
    Coma, S
    Noé, V
    Ciudad, CJ
    ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 2002, 12 (05): : 311 - 325
  • [50] Differential effects of estrogen-dependent transactivation vs. transrepression by the estrogen receptor on invasiveness of HER2 overexpressing breast cancer cells
    Patki, Mugdha
    Salazar, Marcela d'Alincourt
    Trumbly, Robert
    Ratnam, Manohar
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2015, 457 (03) : 404 - 411
12345